Hikma sees 23% growth in full-2013 revenue

February 17, 2014 12:53 am

Jordan’s Hikma Pharmaceuticals has said its full-year revenue is expected to grow 23%, up from its prior forecast of about 20%, thanks to a strong performance in its injectables and generics businesses towards the end of 2013, Reuters has reported. The London-listed company also raised its full-year generics revenue forecast to $270m, as sales of the antibiotic continued to rise. Hikma has already raised its 2013 revenue forecast three times and said in November that it expected revenue from its generics unit to be about $260m.